These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37272195)

  • 1. Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy.
    Rosenzveig A; Garg N; Rao SJ; Kanwal AK; Kanwal A; Aronow WS; Martinez MW
    Expert Opin Pharmacother; 2023; 24(12):1349-1360. PubMed ID: 37272195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Sebastian SA; Padda I; Lehr EJ; Johal G
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):519-532. PubMed ID: 37526885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
    Dong T; Nissen S; Ospina S; Desai MY
    Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond.
    Gaballa A; Jadam S; Desai MY
    Expert Opin Pharmacother; 2024 May; 25(7):915-924. PubMed ID: 38813944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.
    Dong T; Alencherry B; Ospina S; Desai MY
    Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents.
    Hajj Ali A; Mehra N; Desai MY
    Expert Opin Investig Drugs; 2023; 32(9):849-853. PubMed ID: 37787068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol.
    Seo K; Yamamoto Y; Kirillova A; Kawana M; Yadav S; Huang Y; Wang Q; Lane KV; Pruitt BL; Perez MV; Bernstein D; Wu JC; Wheeler MT; Parikh VN; Ashley EA
    Circulation; 2023 Nov; 148(21):1691-1704. PubMed ID: 37850394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Pharmacotherapy in Hypertrophic Cardiomyopathy.
    Andries G; Yandrapalli S; Naidu SS; Panza JA
    Cardiol Rev; 2018; 26(5):239-244. PubMed ID: 29746257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
    Desai MY; Owens A; Geske JB; Wolski K; Saberi S; Wang A; Sherrid M; Cremer PC; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Balasubramanyam A; Lampl K; Sehnert AJ; Nissen SE
    Circulation; 2023 Mar; 147(11):850-863. PubMed ID: 36335531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
    Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I
    Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives.
    Ammirati E; Contri R; Coppini R; Cecchi F; Frigerio M; Olivotto I
    Eur J Heart Fail; 2016 Sep; 18(9):1106-18. PubMed ID: 27109894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
    Yacoub MS; El-Nakhal T; Hasabo EA; Shehata N; Wilson K; Ismail KH; Bakr MS; Mohsen M; Mohamed A; Abdelazim E; Ali HT; Soliman Z; Sayed A; Abdelsayed K; Caliskan K; Soliman O
    Heart Fail Rev; 2024 Mar; 29(2):479-496. PubMed ID: 38112937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
    Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP
    Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypertrophic cardiomyopathy (HCM). Surgical versus drug therapy].
    Schulte HD; Gramsch-Zabel H; Schwartzkopff B; Gams E
    Z Kardiol; 1999 Mar; 88(3):163-72. PubMed ID: 10355066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy.
    Packard E; de Feria A; Peshin S; Reza N; Owens AT
    Cardiol Ther; 2022 Dec; 11(4):491-507. PubMed ID: 36243823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
    Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
    Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management.
    Sykuta A; Yoon CH; Baldwin S; Rine NI; Young M; Smith A
    Ann Pharmacother; 2024 Mar; 58(3):273-285. PubMed ID: 37329113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obstructive hypertrophic cardiomyopathy: a review of new therapies.
    Mehra N; Ali AH; Desai MY
    Future Cardiol; 2023 Oct; 19(13):661-670. PubMed ID: 37933625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of peak provoked left ventricular outflow tract gradients on clinical outcomes in hypertrophic cardiomyopathy.
    Lu DY; Hailesealassie B; Ventoulis I; Liu H; Liang HY; Nowbar A; Pozios I; Canepa M; Cresswell K; Luo HC; Abraham MR; Abraham TP
    Int J Cardiol; 2017 Sep; 243():290-295. PubMed ID: 28747034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.